Research Paper Volume 13, Issue 15 pp 19375—19396

Figure 2. BM-MSCs promote the angiogenesis of GC in vivo and the tube formation and migration of HUVECs in vitro following H. pylori stimulation. (A) Representative images of the blood vessels of SGC co-injected with or without BM-MSCs or H. pylori -pretreated BM-MSCs in the CAM assay over 4 days. n= 10 eggs in each group. (B) Quantification of the vascular density growth rate in the CAM assay. (C, D) SGC cells mixed with or without BM-MSCs or H. pylori-pretreated BM-MSCs were injected into BALB/c nude mice, and tumor volumes were monitored every two days. n= 3 mice in control group and 5 mice per group in other groups (E) Average tumor weights from nude mice. (F) Representative images of H&E staining and Ki-67 and CD31 (PECAM1) IHC staining of tumors. (G, H) Quantification of Ki-67 and CD31. (I) Angiogenesis fluorescent agent AngioSense 750EX in tumors. (J) Quantification of I. (K) The migration ability of HUVECs was evaluated using a Transwell assay. n= 3 wells per group. (L) Quantification of K. (M) In vitro tube formation to investigate the effect of CM from BM-MSCs on HUVEC tube formation. n= 5 wells per group. (N) Quantification of M.